GlassScriptPhysician profile
Crystal L Parks
NPI 1760748172
$2,626.83
in general payments reported to CMS, 2019-2025
20 companies · $660 in 2025
The $660 reported for 2025 was more than what 78% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $857 · 2022: $69.63 · 2023: $446 · 2024: $595 · 2025: $660.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,701.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,700.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $570.01 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $400.57 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Astrazeneca Pharmaceuticals LP | $302.85 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Glaxosmithkline, LLC. | $206.09 | 2019-2024 | Trelegy Ellipta |
| Amgen INC. | $195.27 | 2023-2025 | Repatha, Otezla, Otezla |
| Janssen Pharmaceuticals, INC | $190.21 | 2019-2023 | Xarelto |
| Sanofi-Aventis U.S. LLC | $130.17 | 2019-2025 | |
| Abbvie INC. | $91.62 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $85.48 | 2019-2022 | |
| Corium, LLC | $76.82 | 2025 | Azstarys |
| Astellas Pharma US INC | $68.51 | 2024-2025 | Veozah |
| Exact Sciences Corporation | $64.60 | 2023-2024 | Cologuard Collection Kit |
| Abbott Laboratories | $60.17 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $42.84 | 2025 | Caplyta |
| Pfizer INC. | $40.86 | 2023-2025 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $36.28 | 2019-2024 | Xifaxan, Trulance |
| Amarin Pharma, INC. | $18.96 | 2019 | |
| Phathom Pharmaceuticals, INC. | $17.94 | 2024 | Voquezna |
| Merck Sharp & Dohme LLC | $14.58 | 2019 | |
| Dexcom, INC. | $13.00 | 2023 | Dexcom G6 Transmitter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Crystal Parks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.